CRD-740 for Cardiovascular Diseases

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Cardurion Investigative Site, Tullahoma, TN
Cardiovascular Diseases+4 More
CRD-740 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a drug to see if it can help people with two types of heart failure. CRD 740 is a drug that is used to treat cardiovascular diseases. This drug has been previously approved by the FDA for another condition.

Eligible Conditions

  • Cardiovascular Diseases
  • Heart Diseases
  • Adrenal gland hypofunction
  • Heart Failure With Preserved Ejection Fraction (HFpEF)
  • Heart Failure

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Cardiovascular Diseases

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: Baseline to Week 12

Baseline to Week 12
Part A: The change in NT-proBNP from baseline (Day 1) to Week 2, from Week 2 to Week 4, and from Week 2 to Week 12.
Part B: The change from baseline (Day 1) in NT-proBNP at Week 12.
Part B: The change from baseline (Day 1) in plasma BNP at Week 12.
Part B: The change from baseline (Day 1) in plasma cGMP at Week 12.
Part B: The change from baseline (Day 1) in the KCCQ-23-CS at Week 12.
Part B: The proportion of subjects with ≥5-point improvement from baseline in the KCCQ-23- CS at Week 12.
Baseline to Week 4
Part A: The change from baseline (Day -1) in plasma cGMP at Week 4.

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Cardiovascular Diseases

Trial Design

2 Treatment Groups

CRD-740
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group

660 Total Participants · 2 Treatment Groups

Primary Treatment: CRD-740 · Has Placebo Group · Phase 2

CRD-740
Drug
Experimental Group · 1 Intervention: CRD-740 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to week 12
Closest Location: Cardurion Investigative Site · Tullahoma, TN
Photo of tennessee 1Photo of tennessee 2Photo of tennessee 3
2022First Recorded Clinical Trial
2 TrialsResearching Cardiovascular Diseases
1 CompletedClinical Trials

Who is running the clinical trial?

Cardurion Pharmaceuticals, Inc.Lead Sponsor
1 Previous Clinical Trials
20 Total Patients Enrolled
1 Trials studying Cardiovascular Diseases
20 Patients Enrolled for Cardiovascular Diseases
Pirouz Shamszad, MDStudy DirectorExecutive Director, Clinical Research

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are at least 18 years of age, and are either male or female.
Subjects with atrial fibrillation or flutter at screening are required to have an NT-proBNP level of ≥1000 pg/mL at screening.
You have echocardiographic evidence of left atrial enlargement.
Subjects with atrial fibrillation or flutter at screening are required to have an NT-proBNP level of ≥500 pg/mL at screening.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.